08 mar: Indre værdi af SmallCap Danmark A/S er opgjort til 20,6 kr. pr. a..
08 mar: Indkaldelse ti ordinær generalforsamling i Investeringsforeningen..
08-03-2019 04:00:57

Lundbeck appoints Keld Flintholm Jørgensen as EVP and Chief Business Officer

Valby, Denmark, 8 March 2019 - H. Lundbeck A/S (Lundbeck) today announced the appointment of Keld Flintholm Jørgensen to the role of Chief Business Officer (CBO) heading Corporate Strategy & Business Development from 4 April 2019. Keld will be part of Executive Management in his role as Executive Vice President, CBO.

The new position is established as part of the revised strategy which focuses on achievement of sustainable growth. This focus demands that Lundbeck supplements its internally generated pipeline with high quality assets from external sources. We will access this external innovation through product license and/or acquisitions as well as through strategic partnerships.

Keld will join the company from a position as Global Head of Strategic Partnering for Roche. Since 2011 Keld has worked in business development and partnering across multiple therapy areas, including CNS. During this period, he has been leading multiple global M&A projects, pharma and biotech partnering initiatives and strategic projects, building creative partnerships and deals to expand the Roche pipeline. Keld was born in Denmark and holds a BSc in Economics and Business Administration and a MSc in Business Economics and Auditing from Copenhagen Business School.

I am looking forward to having Keld join the Lundbeck team, adding his expertise to our Expand and Invest for Growth strategy,” says Deborah Dunsire; President and CEO of Lundbeck. “Creating this additional executive role allows for sufficient management resources devoted to ensuring that we can continue growing our commercial presence and deliver on our growth strategy including access to appropriate external innovation.

I am very pleased to be joining Lundbeck and look forward to be driving the development and execution of the corporate strategy going forward. In addition to the company’s core business, the intention is to devote significant time and effort to pursuing external opportunities which offers significant opportunities for value creation” says Keld Jørgensen.

Following today’s announcement, the executive management of Lundbeck is comprised of:

  • Deborah Dunsire, President & CEO
  • Peter Anastasiou, EVP, North America
  • Lars Bang, EVP, Product Development & Supply
  • Anders Götzsche, EVP & CFO
  • Keld Flintholm Jørgensen, EVP & CBO (as of 4 April 2019)
  • Johan Luthman, EVP, R&D
  • Jacob Tolstrup, EVP, Commercial Operations

Lundbeck contacts

Investors:                                                                                 Media:

Palle Holm Olesen                                                                   Mads Kronborg

Vice President, Investor Relations                                           Senior Director, Corp. Communication

PALO@lundbeck.com                                                             MAVK@lundbeck.com         

+45 30 83 24 26                                                                      +45 36 43 40 00

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

Attachment

logo.jpg

Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
15 maj
DANSKE
Meget interessant refleksion skrevet af Maui. Det kan vores medier godt lære lidt af. Det der kommer..
25
15 maj
PNDORA
I gaar aftes sad jeg og kiggede lidt naermere paa guidance fra Pandora for FY2019, som de meldte ud ..
22
18 maj
OMXC25
Et stort flertal af klimaforskerne mener klimaændringerne er menneskeskabte. Dvs. de uddannede perso..
20
14 maj
E:THIN
Så sidder jeg her og glor på mit depot. Thinfilm falder ekstra meget i øjnene med afkast på minus 96..
20
17 maj
VELO
Hej Alle,   Har siddet og kigget på regnskabet, for at finde ud af hvordan 2019 ender. Umiddelbart e..
16
15 maj
DANSKE
Apropos skribent 6212.. Og Danske Bank..Ja så må man lade vedkommende at han/hun fik ret. Han anbefa..
16
14 maj
DANSKE
Sjovt at der ikke er nogen kritik af SKATs manglende kontrolindsats i forbindelse med momssvindlen, ..
16
18 maj
VWS
Ditlev.. Havde store ambitioner, og store armbevægelser .. Ikke alt gik godt.. Men finanskrisen kan..
15
18 maj
ZEAL
Nedenfor er det samlet udskift af Q1 telefonkonferencen for Zealand Pharma.    Jeg har først trukket..
15
18 maj
OMXC25
Når man begynder at bruge børn som Greta Thunberg for at fremhæve et budskab ringer advarselsklokker..
14

Finanskommentaren: Federal Reserve skal nok redde Trump — også denne gang

15-05-2019 06:00:00
Af ansvarshavende chefredaktør Lars ChristensenUroen er kommet tilbage på de globale aktiemarkeder, og igen synes det at være frygten for global handelskrig, der har udløst den. Samtidig har stigende geopolitiske bekymringer - særligt i relation til Iran - presset olieprisen op, hvilket yderligere synes at have bidraget til at trykke stemningen på de globale aktiemarkeder.Den stigende bekymring ha..

Finanskommentaren: Har konflikten mellem USA og Iran kurs mod Tanker War 2?

Relaterede nyheder
16-05-2019 07:00:00
Generalsekretær, ph.d. Lars Bangert Struwe, AtlantsammenslutningenIndenfor de seneste dage har der været angreb på fire tankskibe og på olieinstallationer ud for de Forenede Arabiske Emirater ved Hormuz-strædet og ved Saudi Arabien. Samtidig kører rygtestrømmen endog meget heftigt i USA og i sikkerhedspolitiske kredse om et muligt amerikansk angreb på Iran. Et sådant angreb vil have markante følge..

Vestas henter endnu en ordre fra Buffett-selskab

Relaterede nyheder
16-05-2019 11:09:05
Vestas kan for anden gang på få dage løfte sløret for en ordre afgivet af et datterselskab til Warren Buffetts investeringsselskab, Berkshire Hathaway Energy.Denne gang er der tale om en ordre på 228 megawatt (MW), som datterselskabet Pacificorp har bestilt til opsætning i vindprojektet Ekola Flats på 250 MW i Wyoming.Ordren omfatter møller af typen V136-4,2 MW i en optimeret version på 4,3 MW, og..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. maj 2019 04:40:56
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190514.2 - EUROWEB4 - 2019-05-20 04:40:56 - 2019-05-20 04:40:56 - 1 - Website: OKAY